Diagnos (ADK) Price & Analysis

Compare

23 Followers

ADK Stock Chart & Stats

C$0.36

C$0.03(9.38%)

At close: Jan 08 4:00 PM EST

C$0.36

C$0.03(9.38%)

Day’s Range― - ―

52-Week RangeC$0.18 - C$0.42

Previous CloseN/A

Volume270.50K

Average Volume (3M)342.67K

Market Cap

C$35.52M

Enterprise ValueC$31.65M

Total Cash (Recent Filing)C$3.40M

Total Debt (Recent Filing)C$2.00M

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Jun 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding120,412,550

10 Day Avg. Volume531,548

30 Day Avg. Volume342,665

Financial Highlights & Ratios

PEG Ratio-0.45

Price to Book (P/B)-6.56

Price to Sales (P/S)117.69

P/FCF Ratio-9.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet RepairEquity turning positive after prior deficits provides a durable solvency buffer and improves creditor and investor confidence. That repaired equity base reduces immediate insolvency risk, slightly eases refinancing options, and creates a firmer platform to pursue operational recovery.

Lean Operating FootprintA small headcount implies a low fixed-cost structure and more flexible cost base, which helps extend runway during prolonged losses. For a healthcare information services firm, a lean team can enable faster decision cycles and more efficient deployment of capital toward product development or sales.

Favorable Industry ExposureOperating in healthcare information services benefits from secular digitalization and ongoing demand for clinical/administrative software and data tools. This structural tailwind supports a large addressable market and enduring demand if the company can stabilize execution and product-market fit.

Bears Say

Declining RevenueA persistent revenue decline (TTM -13.7%) signals eroding market traction and weak product adoption. Over months this reduces economies of scale, makes fixed cost absorption harder, and raises the bar for any turnaround since revenue growth is central to restoring margins and funding operations organically.

Negative Profitability Across All LevelsConsistent negative gross profit through net income indicates structural margin problems rather than one-off items. Without sustainable positive unit economics, the company cannot self-fund growth, limiting reinvestment into sales or R&D and increasing reliance on external capital over the medium term.

Ongoing Cash Burn And LeverageOperating and free cash flow are deeply negative (~-3.78M TTM) while debt remains sizable versus equity, creating elevated refinancing and dilution risk. Persistent cash burn plus structural leverage constraints reduce financial flexibility and increase the chance of capital raises or creditor pressure within months.

Diagnos News

Diagnos to Showcase AI Eye-Health Platform at Toronto Growth Investor Conference

Diagnos ( ($TSE:ADK) ) just unveiled an announcement. Diagnos Inc., a Canadian AI-driven medical imaging specialist focused on...

19d ago

Diagnos Wins $1M-Plus Federal Backing for Next-Generation Retinal AI Research

The latest announcement is out from Diagnos ( ($TSE:ADK) ). Diagnos Inc. and Montreal-based engineering school École de...

1M ago

Diagnos Hires Investor Brand Network to Boost Market Visibility

An announcement from Diagnos ( ($TSE:ADK) ) is now available. Diagnos Inc. has engaged Investor Brand Network (IBN)...

2M ago

Diagnos Advances Global Regulatory Push for AI Eye-Health Platform CARA

An announcement from Diagnos ( ($TSE:ADK) ) is now available. Diagnos Inc. has outlined significant progress in its...

2M ago

DIAGNOS Appoints New Chief AI Scientist to Propel Healthcare Innovation

The latest announcement is out from Diagnos ( ($TSE:ADK) ). DIAGNOS has appointed Dr. Ismail Ben Ayed as...

3M ago

Diagnos Inc. Closes $4 Million Oversubscribed Private Placement

Diagnos ( ($TSE:ADK) ) has provided an announcement. Diagnos Inc. has successfully closed an oversubscribed $4 million brokered...

3M ago

Diagnos Inc. Upsizes Private Placement to $3.65M Amid Strong Demand

Diagnos ( ($TSE:ADK) ) just unveiled an update. Diagnos Inc. has announced an increase in its brokered private...

4M ago

Diagnos Inc. Extends Stock Warrant Exercise Period

Diagnos ( ($TSE:ADK) ) has issued an update. Diagnos Inc. has announced its intention to extend the exercise...

4M ago

Diagnos Inc. Launches $2 Million Private Placement to Support Growth

Diagnos ( ($TSE:ADK) ) has shared an announcement. Diagnos Inc. has announced a brokered private placement led by...

4M ago

DIAGNOS Appoints Philippe Couillard as Chairman Amid Expansion Efforts

Diagnos ( ($TSE:ADK) ) has issued an announcement. DIAGNOS has appointed Dr. Philippe Couillard as the Chairman of...

5M ago

ADK FAQ

What was Diagnos’s price range in the past 12 months?

Diagnos lowest stock price was C$0.18 and its highest was C$0.41 in the past 12 months.

What is Diagnos’s market cap?

Diagnos’s market cap is C$35.52M.

When is Diagnos’s upcoming earnings report date?

Diagnos’s upcoming earnings report date is Jun 04, 2026 which is in 81 days.

How were Diagnos’s earnings last quarter?

Diagnos released its earnings results on Feb 25, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.

Is Diagnos overvalued?

According to Wall Street analysts Diagnos’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Diagnos pay dividends?

Diagnos does not currently pay dividends.

What is Diagnos’s EPS estimate?

Diagnos’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Diagnos have?

Diagnos has 120,412,550 shares outstanding.

What happened to Diagnos’s price movement after its last earnings report?

Diagnos reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.

Which hedge fund is a major shareholder of Diagnos?

Currently, no hedge funds are holding shares in TSE:ADK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Diagnos Stock Smart Score

Outperform

Insider Transactions

Bought Shares

Worth C$95.0K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

86.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Diagnos

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.